News

A 28-year-old woman visited urgent care complaining of an erythematous rash. She also had a sore throat, spiking fever and arthralgias. What's your diagnosis?

MRI-guided treat-to-target treatment for patients with rheumatoid arthritis is no better than conventional treat-to-target strategies, researchers reported in JAMA in February. However, in a new commentary posted this month in JAMA, researchers raise some interesting points experts may want to reconsider.

In an effort to determine what causes immune mediated diseases such as ankylosing spondylitis, inflammatory bowel disease and psoriasis, researchers have focused on learning more about genetic pathogenic pathways responsible for autoimmunity. In this article, we review the data and highlight best practices.

Rheumatoid arthritis patients who failed first-line methotrexate achieved better outcomes with upadacitinib monotherapy, shows a new clinical trials report.

Rheumatoid arthritis patients treated with baricitinib at any point during their treatment, experience improved outcomes, a new clinical trials report shows.

Women who have primary Sjögren’s Syndrome also have decreased lifetime exposure to estrogen, a new study finds.

Children born to women who have rheumatoid arthritis during pregnancy could experience life-long health effects due to changes to DNA that alter genetic activity, new research indicates.

Sjögren’s Syndrome affects American Indians at a higher rather rate than other ethnic groups, but the lack of classically-associated disease symptoms makes diagnosis difficult, new research shows.

Nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with a number of risk factors that can heighten a patient’s risk of major toxicity. Researchers reporting in Arthritis and Rheumatology have come up with a scoring system to measure a patient’s risk of developing major toxicity from NSAID use.

An all-star team of physicians give their takes on how the science behind keeping million dollar athletes on the field has impacted the care patients receive every day.

Patients with systemic lupus erythematosus (SLE) are at an increased risk for fractures, new research shows. The risk is particularly high among patients with lupus nephritis.

Fatigue in patients with systemic lupus erythematosus (SLE) has been linked to anti-NR2 antibodies, which responds to treatment with belimumab, a study shows.

A new study reframes rheumatoid arthritis, broadly considered to be a connective tissue disorder, as having deeper neurological ties.

A pair of phase 3 studies showed 20% symptomatic improvement in patients with psoriatic arthritis who were treated with guselkumab.

Lutikizumab does not improve pain or imaging outcomes for patients with erosive hand osteoarthritis, according to new research.

While gout does not increase the risk of death post-acute coronary syndrome, a new study shows the condition does increase an individual’s risk for readmission after heart failure, as well as the number of days he or she will spend on the hospital.

Even when comorbidities or poor prognosis are considered, osteoporosis specifically, severely raises the risk of hip fracture for women aged 80 or older.

A trio of phase 3 psoriatic arthritis trials showed that 30 mg of apremilast, twice daily, increased the likelihood of achieving low disease activity or remission.

A new study of long-term data demonstrates that infliximab and golimumab are both effective, safe treatments for symptoms of ankylosing spondylitis.

It’s not just weight that could be contributing to degenerative changes in obesity-related osteoarthritis. In this Q&A, Dr. Clifford J. Rosen, director of the Center for Clinical and Translational Research, Maine Medical Center Research Institute, Portland, discusses the mechanisms of osteoarthritis.

Interim results at 24 weeks show that 75.3% of patients treated with tildrakizumab achieved a 20% improvement compared to 50.6% with placebo.

In the phase 3b/4 ORAL Shift study, tofacitinib monotherapy was shown to be comparable to tofacitinib with methotrexate.

Three studies presented this weekend at EULAR in Madrid suggest that being overweight or obese can heighten the severity or arthritic disease.

The overall risk of cancer in psoriatic arthritis patients who are treated with TNF inhibitors  doesn’t appear to be linked to their treatment, according to a study presented EULAR this weekend.

A pilot study presented this weekend at EULAR suggests that electro stimulation of the vagus nerve reduces rheumatoid arthritis symptoms.

A 24-week trial of tildrakizumab to treat the skin and joint conditions associated with psoriatic arthritis shows promise as a possible new treatment, shows a study presented at EULAR.

An intensive treatment strategy that combines ebuxostat (Uloric, Takeda) and the novel verinurad, significantly reduced hyperuricemia and albuminuria in patients with type 2 diabetes patients.

A new study of AbbVie’s original JAK1-selective inhibitor indicates that it outdoes adalimumab without sacrificing safety in rheumatoid arthritis treatment.

Lupus nephritis remained in remission for over 10 years in a group of patients who were treated with cyclosporine A, mycophenolate mofetil or azathioprine, shows a study presented at the European Congress of Rheumatology (EULAR) annual meeting this weekend in Madrid.

Patients with rheumatoid arthritis receiving combination treatment were more likely to reach ACR20, ACR50, and ACR70 than those receiving methotrexate monotherapy.